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Lung cancer is the most common cause of cancer mortality worldwide, with an estimated 1.4 million deaths
each year.Herewe report whole-exome sequencing of nine tumor/normal tissue pairs fromChinese patients
with non-small cell lung carcinoma (NSCLC). This allows us to identify a number of significantly mutated
genes in NSCLC, which were highly enriched in DNA damage repair, NF-kB pathway, JAK/STAT signaling
and chromatin modification. Notably, we identify a histone-lysine methyltransferase gene, namely, MLL2,
as one of the most significantly mutated genes in our screen. In a following validation study, we identify
deleterious mutations of MLL2 in 12 out of 105 (11.4%) NSCLC patients. Additionally, reduced or lost
expression of MLL2 was commonly observed in tumor tissues as compared with paired adjacent non-tumor
tissues regardless of mutation status. Together, our study defines the landscape of somatic mutations in
Chinese NSCLC and supports the role of MLL2 mutation in the pathogenesis of the disease.
L
ung cancer is themost commonly diagnosed cancer as well as the leading cause of cancer deaths worldwide. It
has been classified into two major types, including NSCLC and small cell lung cancer (SCLC)1. About 85
percent of all lung cancers are identified as NSCLC, which comprises three histological subtypes: adeno-
carcinoma (ADC), squamous cell carcinoma (SCC) and large cell lung carcinomas (LCC)1,2. Although great
efforts have been made to develop new diagnostic and therapeutic approaches for lung cancer, however, the
prognosis remains poor due to diagnosis at an advanced stage and a high rate of recurrence1.
Cancer is a highly heterogeneous disease associated with various environmental exposures and genetic sus-
ceptibility which leads to unrestrained cell proliferation and neoplasm formation. The accumulation of somatic
DNA alterations is considered as one of the contributing factors in carcinogenesis2–4. These alterations can occur
at different levels from point mutations to gain or loss of large DNA fragments, resulting in altered expression of
the corresponding genes or impaired protein functions. Over the last few years, extensive research has investi-
gated the genetic alterations associated with lung cancer2,5–9. These efforts have led to the discovery of several
reproducible alterations underlying disease and have already proven successful to facilitate clinical decision
making in NSCLC1,10,11. For example, genetic abnormality of the tumor suppressor gene TP53 is commonly
observed in patients and has been shown to be associated with poorer survival prognosis and increased cellular
resistance to therapy1,5. Activating EGFR mutations, observed in about 15% NSCLC patients, are associated with
increased sensitivity to EGFR tyrosine kinase inhibitors. Consequently, EGFR has become a target for anti-cancer
drug therapy while evaluation for EGFR mutation status is used as a standard of care in advanced-stage
NSCLC8,12. KRAS plays an important role in regulating several signaling pathways downstream from EGFR
and are also found to be frequently mutated in NSCLC13. In line with this, KRASmutations and EGFRmutations
are found to be mutually exclusive in larger series of patients. Additionally, recent large-scale, whole genome
sequencing studies have identified frequent mutations in tumor suppressors such as NF1, RB1, NF1, CDKN2A,
SMARCA4 and KEAP15–7,14,15. Activating mutations in BRAF, ERBB4, and PIK3CA which are associated with
tumor cell growth and survival are also found to be common16–18. Moreover, recurrent somatic mutations in the
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splicing factor gene U2AF1, chromatin remodeling gene ARID1 and
matrix remodeling protein MXRA5 have also been reported9,19,20.
These findings have largely expanded our understanding of the dis-
ease mechanisms, providing useful information on novel therapeutic
targets and predictive biomarkers.
Here we used massively parallel sequencing to sequence the
exomes of nine NSCLCs and matched normal adjacent tissue pairs.
This allows us to identify a number of known and previously unre-
ported genes that are significantlymutated in these patients. Pathway
analysis and network reconstruction revealed several key signaling
cascades affected in NSCLC including cell-cycle progressing, JAK/
STAT signaling and chromatin remodeling. These results provide
new insights into the molecular pathogenesis of NSCLC in Chinese
patients.
Results
Overview of genetic alterations. In this study, we performed whole-
exome sequencing of paired tumour/control DNA from nine
Chinese patients with NSCLC, including eight ADCs and one SCC,
with a mean depth of 1043 and 93.8% of bases covered to at least
203 (Table 1, Supplementary Table 1). Altogether we identified 3618
high-confidence somatic mutations, of which 1556 (43%) were in
protein coding regions. These NSCLCs display a large variation in
the number of somatic mutations (Supplementary table 2), with a
mean of 132 nonsynonymous and 40 synonymous mutations in
protein-coding sequences as well as 229 mutations in introns or
intergenic regions (Table 1, Supplementary Tables 2, 3). In line
with previous results5,6,9,15,17, we found that tumors from smokers
(smk) have significantly higher number of exonic mutations
compared to nonsmokers (nonsmk) (324 6 119 per smk vs 52 6
16 per nonsmk, p5 0.001, Student’s t-test). Consistent with previous
studies9,16,17, we observed that mutations occurred predominantly at
G:C base pairs (69.1%), withG:C.A:T (14.7%), C:G.T:A (14.2%),
C:G . A:T (12.2%) and G:C . T:A (11.9%) to be the most
commonly observed transversions.
We then selected a subset of nonsynonymous mutations from
genes that are mutated in multiple patients for further validation.
Using Sequenom MassARRAY genotyping, we validated 101
out of the 108 (93.5%) nonsynonymous mutations examined
(Supplementary Table 3), indicating a very low false-positive rate
of our results. Possible impact of all nonsynonymous substitutions
were predicted based on functional prediction algorithms PolyPhen
and Grantham, as well as conservation prediction algorithms
PhastCons and GERP. Altogether, 533 out of 1190 (44.8%) nonsy-
nonymous mutations were predicted to be highly deleterious as sup-
ported by three or four algorithms (Supplementary Table 4).
Frequently mutated genes in NSCLC. This systematic approach
allowed us to identify several well-described target genes as well as
a number of previously unreported genes that are recurrently
mutated in our NSCLC cohort. Notably, we found nonsynony-
mous mutations in 62 census cancer genes as reported in
Catalogue of Somatic Mutations in Cancer (COSMIC) database,
indicating that they were highly mutated in NSCLC and causally
linked to the pathogenesis of the disease. This included many
known genes associated with lung cancer, such as TP53, EGFR,
KRAS and ERBB4. Indeed, TP53 was the second most frequently
mutated gene identified in this study, with two nonsense and three
missense mutations in five tumor samples (56%). A missense
mutation and a mutation in 59-UTR region of EGFR were
identified in two different samples. We also found one missense
mutation of KRAS and one missense mutation of ERBB4 in
different patients. TTN is the most frequently mutated proteins in
our studywhich contains 13missensemutations in 6 out of 9 samples
(67%). This is consistent with results from COSMIC that 244 out of
the 467 (52%) lung cancer samples sequenced have somatic muta-
tions in TTN. TTN encodes a very large, high abundant protein of
striated muscle. However, considering the large size of the protein
and prevalence of TTN mutations identified in other studies
unrelated to cancer, it is presently hard to determine whether
mutations in TTN act as drivers or are only passengers in NSCLC6.
We then used MuSiC algorithm21 to identify potential drivers that
have a significant higher mutation rate than background mutation
rates with three independent tests, including FCPT (Fisher’s com-
bined P-value test), LRT (Likelihood ratio test) and CT (Convolution
test) (see method). Altogether we identified nine genes that are
potential cancer drivers supported by all three tests (Table 2, p ,
0.05). Benchmarking the results with TTN gene, we found that TTN
is much less likely to be a cancer driver as predicted by LRT than the
other twomethods (Supplementary Table 5). Based on LRTmethod,
TP53 was identified as most significantly mutated gene, followed by
MLL2, which had three missense and two nonsense mutations in
three out of nine samples (33%). MLL2 is a member of the mye-
loid/lymphoid or mixed-lineage leukemia (MLL) gene family,
encodes a histone lysine methyltransferase that play an important
role in epigenetic regulation of gene expression22,23. Recent studies
showed that MLL2-inactivating mutations were frequently observed
in several cancers19,24–27, establishing it as a novel tumor suppressor.
Frequent mutation of MLL2 was also observed in COSMIC lung
cancer cohort (64 out of 431, 15%), we thus suggest that MLL2might
be a novel cancer gene associated with NSCLC22,27. Additionally, we
found that NEK1, a serine/threonine kinase involved in cell cycle
regulation, was mutated more frequently than expected by chance.
Other significantly mutated proteins include PAPPA2, which
encodes a member of the pappalysin family of metzincin metallo-
proteinases and plays an important role in insulin-like growth factor
signaling pathway. CDH10 encodes a cadherin superfamily, integral
membrane protein that mediates calcium-dependent cell-cell adhe-
sion and might play a significant role in cancer progression and
metastasis.
In addition to mutations, we also identified small insertions/dele-
tions (indels) as well as copy number variations (CNVs) in these nine
patients using different computational approaches (seemethods). All
together we identified 93 high confident indels in these nine samples
(supplementary Table 6). We found indel mutations in several key
Table 1 | Summary metrics of exome sequencing
Sequence reads and coverages Mean
Reads mapped to genome: 99066407.83
Reads mapped to exons: 63947604.22
Data mapped to exons (Mb): 4606.81
Mean depth of exons: 104.24
Coverage of exons (%): 99.57
Average read length (bp): 89.98
Rate of nucleotide mismatch (%): 0.3
Fraction of exon covered .5 10X: 97.15
Fraction of exon covered .5 20X: 93.82
Fraction of exon covered .5 30X: 89.1
Fraction of exon covered .5 40X: 82.82
Fraction of exon covered .5 50X: 75.66
Summary of somatic mutations Mean
Intergenic 21.22
Intron 207.89
Coding-synonymous 39.67
Missense 103
Stop-gained 7.56
Stop-lost 0.44
Splice site 4
39-UTR 11.33
59-UTR 5.89
www.nature.com/scientificreports
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regulators of cell death including NOTCH2, CASPA8AP2, CUL2,
PRUNE2 and RPS27L, as well as those involved in Ras signaling,
including GMIP, ECT2L and ERBB2. We also detected CNV events
in 2870 genes, of which, 301 contains deleteriousmutations and eight
contains indels (supplementary Table 7). For example, we observed
copy number loss in a number of cell cycle regulators including
CKS2, NEK1 and LATS2. However, compared with detecting muta-
tions and indels, extracting information of CNVs from exome
sequencing data is very challenging as the results are highly affected
by sequencing depth and the noncontiguous nature of the captured
exons. We thus suggest that the CNV results reported here should be
interpreted with care.
Altered pathways and gene modules in NSCLC. Although it seems
that the mutations are tremendously diverse and complex, however,
they might disturb genes involved in the same signaling pathway or
regulatory module6,28–30. We thus performed pathway analysis to
identify signaling cascades that contain a larger number of
mutated genes than expected by chance (Supplementary table 8).
Interestingly, mutated genes were significantly enrichment in DNA
damage checkpoint and cell cycle control (Figure 1A). In response to
DNA damage, eukaryotic cells activate ATM/ATR and TP53 to
initiating signaling cascade involved in cell cycle arrest and DNA
repair. Multiple components of the signaling pathway were
mutated in six out of the nine NSCLC cases. Moreover, we also
observed significant enrichment of mutated genes in NF-kB
signaling, which controls the expression of many genes involved in
cell growth and immune responses. Although no somatic mutation
was detected in any components of NF-kB complex, we found
frequent mutations in a wide range of membrane receptors and
their downstream effectors that might result in perturbed NF-kB
function in six cases. As shown in Figure 1B, some of the key
cascades involved EGFR/KRAS pathway, TLR/IRAK-M pathway
and TCR/LCK pathway. Interestingly, in line with previous study5,
we found that JAK-STAT pathway was also significantly disrupted in
NSCLC. JAK-STAT pathway is one of the important signaling
pathways downstream of cytokine receptors, which functions in
plays an important role in regulating cell proliferation and
migration. Somatic mutations in several key components of the
pathway, including JAK, STAT and SOCS (Figure 1C), were
identified in four cases. Moreover, there is growing evidence
suggesting that aberrant epigenetic modifications are playing an
important role in the tumorigenesis. Recurrent mutations of
chromatin-modifying genes have been recently discovered in other
cancers19,24,25,27,31 but their implication in lung cancer had not yet
been reported. Here we found frequent mutations in several
modifiers in six tumors, including some of the most frequently
mutated gene MLL2 (Figure 1D). As epigenetic aberrations are
potentially reversible, targeting abnormal chromatin-modifiers
might be a promising strategy for the treatment of cancer. Other
core signaling pathways that were mutated in at least six patients
included the Axonal Guidance Signaling, Hereditary Breast Cancer
Signaling, PTEN Signaling and p70S6K Signaling, many of which
have been implicated in other cancers (Supplementary Table 8).
We then mapped mutant genes into a global signaling network
using cytoscape32,33 (Supplementary Figure 1A). To enhance quality
of the analysis and to reduce network complicity, only physical
interactions and regulatory interactions were used for network con-
struction. Using GeneMANIA33, we also identified several tightly
connected modules that contains a significantly higher number of
genes involved in the same signaling pathway. Interestingly, we find
that the most significantly affected module is involved in Tyrosin
kinase activity of JAK-STAT cascade (Supplementary Figure 1B).
This is in line with our pathway analysis and supports the roles of
alternations in JAK-STAT module as driver mutations in NSCLC.
Moreover, we also identified a closely connected sub-network that
plays an important role in G2/M transition (Supplementary Figure
1C).
Validation study of MLL2 mutations in NSCLC. The frequent
mutations of genes involved in chromatin modification and the
discovery of MLL2 as one of the most frequently mutated genes in
NSCLC lead us to study this gene in greater detail. We then
resequenced the coding regions of MLL2 in the discovery cohort as
well as an additional 96 NSCLC samples by targeted sequencing. The
two cohorts together encompass 105 NSCLC cancers, including 81
ADC and 24 SCC. Specifically, all exons of MLL2 in each tumor
tissue were amplified using long-range PCR, followed by barcoded
sequencing on the Illumina Genome Analyzer with an average
coverage of ,10003 per sample. After removing known muta-
tions in dbSNP and 1000 Genomes, we resequenced all nonsy-
nonmous mutations in tumor/normal pairs to screen for novel
somatic mutations using Sequenom followed by Sanger sequenc-
ing. All together we identified inactivating mutations or protein
deficiency of MLL2 in 12 out of 105 (11.4%) individuals
(Figure 2A, Table 3), which was similar to that reported in
COSMIC database (64/431, 15%), indicating that MLL2 is
frequently mutated in NSCLC.
We then used quantitative real-time PCR to study MLL2 express-
ion in 23 NSCLC samples with good RNA quality, including the nine
samples in the discovery cohort. Somatic mutations of MLL2 were
identified only in three tumors in the discovery cohort. Interestingly,
we found that MLL2 expression was either silenced or significantly
reduced in all tumor tissues compared with adjacent non-tumor lung
tissues (Figure 2B, C, p 5 4.6 3 1026, Student’s t-test), regardless of
themutation status. All together, we found thatMLL2was frequently
mutated and repressed in NSCLC, supporting its role as a critical
tumor suppressor.
Discussion
Our understanding of the genetic variations that underlie the patho-
genesis of NSCLC has taken great strides during the last few
years5,9,15,16,18. These findings will continue to reshape the landscape
of clinical care by providing useful information regarding diagnosis,
Table 2 | Genes with somatic mutation rates significantly higher than background
Gene Symbol NO. of Mutations Gene Length P value-FCPT P value-LRT P value-CT
TP53 5 2261 1.68E-05 4.96E-08 1.14E-08
MLL2 5 18074 2.66E-03 2.57E-06 1.76E-05
NEK1 2 4366 2.92E-02 6.17E-06 1.12E-04
OR52A1 2 942 7.72E-03 9.85E-06 4.23E-06
IGSF11 3 2739 1.50E-02 3.66E-05 3.76E-05
BBS7 2 2395 3.59E-02 1.08E-04 5.60E-05
PAPPA2 3 7061 4.19E-02 1.79E-04 2.51E-04
CDH10 3 4036 2.46E-02 5.53E-04 9.03E-05
TTN 13 138148 1.21E-03 6.61E-04 4.48E-05
www.nature.com/scientificreports
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prognosis, targeted therapy and clinical trials. Here we performed
exom sequencing of NSCLCs in Chinese patients. This allowed us to
identify a number of previously unreported mutated genes and
pathway alterations in NSCLC, providing evidence of common dys-
function in cell cycle control, NF-kB signaling and chromatin
modification.
In addition to key players in lung cancer such as TP53 and EGFR,
we had also found frequent mutations in several potential cancer
genes yet to be associated with lung cancer in our initial screen.
Among them MLL2 was the most striking novel candidate in
NSCLC. MLL2 is a histone lysine methyltransferase that forms a
complex with other co-factors including ASH2L, RbBP5, WDR5,
DPY30, PA1 and UTX, which has been shown to play essential roles
in epigenetic regulation of transcription22,34. A recent combinatorial
analysis of the MLL2 binding profile and gene expression profile in
MLL2 knockout cells identified several direct targets of MLL222.
Notably, their results revealed that MLL2 binding sites were highly
overlapped with p53-targeted regions22 and a wide range of genes
involved in p53 pathway, cAMP-mediated signaling, and cholestasis
signaling were significantly downregulated inMLL2 knockout cells22.
Moreover, recent genetics studies also found mutations in MLL2 or
other genes encoding subunits of MLL2 complex to be common in a
variety of cancer types19,22,24,25,27,31, supporting its role as a tumor
suppressor. MLL2 protein contains several evolutionarily conserved
domains including clusters of PHD (plant homeodomain) domain at
the N-terminus, and a SET (suppressor of variegation, enhancer of
zeste, trithorax) domain at the C-terminus, which is essential for the
DNA binding ability of MLL2. In our validation screen for MLL2
somaticmutation, we identified a high proportion of nonsensemuta-
tions which result in truncated proteins of MLL2 lacking the SET
domain (Figure 2A).
Interestingly, we observed that MLL2 expression was significantly
repressed in tumor tissues compared with adjacent normal tissues.
We found no evidence that reduced expression of MLL2 is caused by
mutations, as MLL2 expression is also reduced in tumor samples
bearing noMLL2mutation. We also found no indels, CNVs or other
structural variations of MLL2 in our exome sequencing data
(Supplementary Table 6–7). This suggest that MLL2 expression in
tumors might be caused by reduced transcription or RNA stability.
Whichever the cause, altered expression of MLL2may abolish MLL2
mediated histone methylation activities and disrupt expression of
downstream target genes. We then asked whether mutation and
low expression ofMLL2 are prognostic for poor lung cancer survival.
Using UCSC cancer browser database35,36, we obtained MLL2 muta-
tion spectrum, expression profile and clinical information of a cohort
of 167 TCGA lung squamous cell carcinoma (LUSC) patients.
Interestingly, we found that patients bearing MLL2 mutations are
more likely to have worse survival outcome than those with normal
MLL2 (Supplementary Figure 1A, Log Rank p 5 0.07), supporting
the role of mutant MLL2 in driving tumor growth and progression.
In contrast, no significant difference was observed between patients
with relative high or low MLL2 expression in tumors samples
(Supplementary Figure 1B, Log Rank p 5 0.53). However, we might
not be able to draw a substantive conclusion at this stage as the
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number of cases with MLL2 mutation was small (n 5 33). Future
large scale sequencing or functional studies are required to invest-
igate the role of MLL2 in NSCLC.
Personalized medicine with targeted therapy is a major improve-
ment over conventional chemotherapy1,3,11,37. For example, targeted
therapy for EGFR has proven successful in treatment of patients with
sensitive mutations and is now considered to be the standard of care
in advanced-stage NSCLC1,8,12. Cancer genome sequencing is thus
essential to selecting appropriate therapy strategies and finding novel
therapeutic targets. In addition to EGFR, we had identified several
mutated genes that were potential therapeutic targets for the treat-
ment of NSCLC38, including ABL2, BCL11A, FLT3, JAK2, KIT,
MMP3, MTOR, PARG, PI3K, RAD51, AP1, RXRA and TLR4.
Comprehensive identification of therapeutic targets and incorpora-
tion ofmolecular testing in clinical decisionmaking will hold a key to
improving NSCLC patients’ outcomes in the future.
Methods
Tumor tissues. 105 pairs of fresh frozen NSCLC tumors and matched adjacent
normal lung tissues, including nine pairs used for exome sequencing, were obtained
from the Pathology Core at Shanghai Chest hostpital affilitated to Shanghai Jiaotong
University. The clinical information associated with the NSCLC samples used in this
study is provided in Supplementary Table 7. Primary tumor tissues were sectioned,
stained, and reviewed by pathologists before they were micro-dissected to obtain a
high purity of the tumor cells (.90%). The study protocol was approved by
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Table 3 | Mll2 mutations detected in exome sequencing and screening samples
Position Ref Var Type Function Change
chr12:49447023 C C/T ADC missense M307I
chr12:49444329 G A/G SCC frameshift I1015fs
chr12:49438733 C C/T ADC missense R1586H
chr12:49434627 G G/T ADC stop-gained S2309X
chr12:49434618 G A/G ADC missense S2312L
chr12:49433784 G A/G ADC missense S2590L
chr12:49431391 C A/C ADC stop-gained E3250X
chr12:49431181 C C/T SCC missense A3320T
chr12:49430932 C A/C ADC missense A3403S
chr12:49426241 G A/G ADC stop-gained Q4083X
chr12:49426235 G A/G ADC stop-gained Q4085X
chr12:49425577 G A/G ADC missense P4304L
www.nature.com/scientificreports
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institutional review board of Shanghai Chest hospital and Shanghai Institutes for
Biological Sciences. Informed consent was obtained from all subjects and all
experiments were performed in accordance with relevant guidelines.
NimbleGen exome capture and sequencing. The qualified genomic DNA sample
was randomly fragmented by Covaris and the size of the library fragments is mainly
distributed between 250 bp and 300 bp. Then adapters were ligated to both ends of
the resulting fragments. Extracted DNA was then amplified by ligation-mediated
PCR (LM-PCR), purified, and hybridized to the NimbleGen 44 M human exome
array for enrichment. Each captured library was then loaded on Hiseq2000 platform,
and we performed high-throughput sequencing for each captured library. Each
sample was sequenced at the mean depth of 1003 to achieve high sensitivity and
accuracy for mutations detection. Raw image files were processed by Illumina
basecalling Software 1.7 for base-calling with default parameters and the sequences of
each individual were generated as 90 bp pair-end reads.
SNPs and CNVs detection. SOAPaligner39(soap2.21) was used to align the clean
reads to the human reference genome (NCBI human genome assembly build 37).
Based on results from SOAPaligner, software SOAPsnp21 was used to assemble the
consensus sequence and call genotypes in target regions. Small indels were detected
using SOAPindel while CNVs were detected using CEQer40. To minimize false-
positives in somaticmutations, we set theminimum snp quality is equal or larger than
80, minimum coverage as 83 in normal and 153 in tumor, the minimum reads of
variant allele as 5, and theminimum proportion of variant allele as 15% in tumor.We
also filtered mutations reported in HapMap, dbSNP 137 and1000 genomes. Then we
used Seattle Seq Annotation to functionally annotate and categorize somatic variants
detected from diverse genomes. Functional importance of the identified mutations
were predicted based on 1) polyPhen, which predicts the impact of an amino acid
substitution on the structure and function of the protein; 2) Grantham, which
predicts the impact by chemical dissimilarity; 3) PhastCons and 4) GERP which both
predicted conservation of the mutant site by multiple alignments.We considered
nonsynonmous mutations located within a conserved site with strong influence on
protein function to be highly deleterious if they passed at least three out of the four
filters (polyPhenScore . 0.9, granthamScore . 100, scorePhastCons . 0.9 and
consScoreGERP . 3). SeattleSeq Annotation (http://snp.gs.washington.edu/
SeattleSeqAnnotation137/).
Significnatly mutated genes.We use MuSic (the Mutational Significance in Cancer
0.4) to identify significantly mutated genes which have a observable higher mutation
rate than background mutation rates. Several basic elements were inputted into
MuSiC, including the TCGAMAF format files of somatic mutations of 9 lung cancer
patients, the BAM files for the 9 lung cancer samples and their matched normal, and
the target exons regions coordinated with the MAF files above (hg19). We applied
SMG (the significantly mutated gene) test, a module in MuSiC, to compare each
category of nonsynonymous mutation rates to the appropriate BMR. The probability
that a gene contains significantly more mutations was determined by three
independent test including FCPT, LRT and CT integrated as part of the algorithm.
Confirmation of somatic mutations using Sequenom MassARRAY. Subsets of
nonsynonymous mutations from genes that are mutated in multiple patients
identified in our initial screen were selected for validation using Sequenom
MassARRAY platform. Genotyping of each tumor/normal pair involved an initial
locus-specific PCR reaction, followed by single base extension using mass-modified
dideoxynucleotide terminators of a primer which anneals immediately upstream of
the potential polymorphic site. PCR primers and extension primers were designed by
MassARRAY Assay Design 3.1 software with the default parameters. The extension
products were nanodispensed to SpectroCHIP II-G384 chips and analyzed by
MassARRAY Analyzer and MassARRAY Typer 4.0 software.
Pathway analysis and network reconstruction. Ingenuity Pathway Analysis (IPA)
was performed to identify signaling pathways that contain higher number of mutant
genes than expected by chance. Network reconstruction and Gene ontology based
module search was performed with GeneMANIA33 in cytoscape32. Protein pairwise
relationships extracted only from direct protein-protein interactions and curated
pathways. For each node the top 20 related genes and at most 20 attributes were used
using automatic weighting.
Targeted sequencing of MLL2. We used 15 long-range PCR to amplify the coding
regions of the MLL2 gene in 105 NSCLC tumor samples (primers in Supplementary
Table 8). Amplicons of each sample were mixed into 4 pools and used 4 barcode-
tagged primer pairs to prepare libraries for paired-end sequencing analysis on an
Illumina Genome Analyzer II. Altogether, ,5.5 G base pairs of raw data and ,3.6
million pairs of reads were produced with an average coverage of ,10003 in each
sample. After removing known mutations in dbSNP and 1000 Genomes, we
resequenced all nonsynonmous mutations in tumor/normal pairs in each pool to
screen for novel somatic mutations using Sequenom. All somatic mutations reported
in Figure 2A were subsequently confirmed by Sanger sequencing.
Quantitative real-time PCR and pathway analysis.Quantitative real-time PCR was
performed in 23 paired tumor and adjacent non-tumor tissues using the ABI PRISM
7900 System according to themanufacturer’s protocol. MLL2 was amplified usingM-
F: 59-GGAGCTGCCACTCATGATCA-39 and M-R: 59-
TGTTGGTCTCGCCTGTGAAG-39. Housekeeping gene GAPDH (Glyceraldehyde
3-phosphate dehydrogenase) was used as reference and amplified using G-F: 59-
AAGGTGAAGGTCGGAGTCAA-39 and G-R: 59-AATGAAGGGGTCAT-
TGATGG-39. Student’s t-test was used to compare levels of expression between
tumor and adjacent non-tumor tissues.
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